Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice

Over the past few decades, the clinical outcomes of patients with cancer have significantly improved mostly owing to the development of effective chemotherapeutic treatments. However, chronic health conditions such as bone mass loss and risk of fragility fractures caused by chemotherapy have also em...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizaka, Takahiro, Horiuchi, Keisuke, Kondo, Shinya, Isaji, Masashi, Nakagawa, Takahiro, Inoue, Masahiro, Rikitake, Hajime, Taguchi, Eiko, Susa, Michiro, Yoda, Masaki, Ono, Takeshi, Kozai, Yusuke, Chiba, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248043/
https://www.ncbi.nlm.nih.gov/pubmed/37305428
http://dx.doi.org/10.1016/j.bonr.2023.101693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248043/
https://www.ncbi.nlm.nih.gov/pubmed/37305428
http://dx.doi.org/10.1016/j.bonr.2023.101693

Ejemplares similares